Dignitana (DIGN) Q1 2025 earnings summary

Executive summary

• Net sales grew 4% year-over-year to 22.0 MSEK in Q1 2025, with the U.S. market driving most of the increase.

• Operating result improved to -1.6 MSEK from -5.0 MSEK year-over-year; EBITDA turned positive at 0.8 MSEK.

• Net result after financial items was -1.9 MSEK, a significant improvement from -5.1 MSEK in Q1 2024.

• Board recommended acceptance of Paxman AB's public takeover offer, with an EGM scheduled to address board changes.

• Strategic focus on cost control, operational efficiency, and leveraging outsourcing to drive scalability and flexibility.

Financial highlights

• Net sales: 22,011 TSEK (Q1 2025) vs. 21,165 TSEK (Q1 2024).

• EBITDA: 0.8 MSEK (Q1 2025) vs. -1.1 MSEK (Q1 2024).

• Operating result: -1,631 TSEK (Q1 2025) vs. -4,953 TSEK (Q1 2024).

• Net result after financial items: -1,863 TSEK (Q1 2025) vs. -5,056 TSEK (Q1 2024).

• Earnings per share: -0.02 SEK (Q1 2025) vs. -0.07 SEK (Q1 2024).

• Cash and cash equivalents: 2,813 TSEK at quarter end, unchanged year-over-year.

• Average Daily Treatment Revenue (ADTR): 268 TSEK (Q1 2025) vs. 241 TSEK (Q1 2024).

Outlook and guidance

• New U.S. reimbursement codes and New York state legislation effective 2026 expected to drive broader adoption and improved financial accessibility.

• Company expects positive impact from enhanced reimbursement and insurance coverage, with potential for similar legislative actions in other states.

• Management believes current business plans and available credit facilities are sufficient to cover working capital needs for the next 12 months.